Title Page

Title: Monitoring transmission intensity of trachoma with serology: a multi-country study

Authors: Christine Tedijanto[1], Anthony W. Solomon[2], Diana L. Martin[3], Scott D. Nash[4], Jeremy D. Keenan[1,5], Thomas M. Lietman[1,5,6,7], Patrick J. Lammie[8], Kristen Aiemjoy[9], Abdou Amza[10,11], Solomon Aragie[12], Ahmed M. Arzika[13], E. Kelly Callahan[4], Sydney Carolan[1], Adisu Abebe Dawed[14], E. Brook Goodhew[3], Sarah Gwyn[3], Jaouad Hammou[15], Boubacar Kadri[11], Khumbo Kalua[16], Ramatou Maliki[13], Beido Nassirou[11], Fikre Seife[17], Zerihun Tadesse[12], Sheila K. West[18], Dionna M. Wittberg[1], Taye Zeru[19], Benjamin F. Arnold[1,5] *

Author affiliations:
[1] Francis I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA, 94158
[2] Department of Control of Neglected Tropical Diseases, WHO, Geneva, Switzerland
[3] Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA 30329
[4] The Carter Center, Atlanta, GA, USA, 30307
[5] Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA, 94158
[6] Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA 94143
[7] Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94143
[8] Neglected Tropical Diseases Support Center, Task Force for Global Health, Atlanta, GA, USA, 30030
[9] Division of Epidemiology, Department of Public Health Sciences, University of California Davis School of Medicine, Davis, CA, USA
[10] Programme FSS/Université Abdou Moumouni de Niamey, Programme National de Santé Oculaire, Niamey, Niger
[11] Programme National de Lutte Contre la Cecité, Niamey, Niger.
[12] The Carter Center Ethiopia, Addis Ababa, Ethiopia
[13] The Carter Center Niger, Niamey, Niger
[14] Amhara Regional Health Bureau, Bahir-Dar, Ethiopia
[15] Service of Ocular and Otological Diseases, Epidemiology and Disease Control Directorate, Ministry of Health, Morocco
[16] Blantyre Institute for Community Outreach, Malawi
[17] Federal Ministry of Health, Addis Ababa, Ethiopia
[18] Johns Hopkins School of Medicine, Ophthalmology Department, Baltimore, USA, 21287
[19] Amhara Public Health Institute, Bahir-Dar, Ethiopia

* Corresponding Author:
Benjamin F. Arnold, PhD
Associate Professor
F.I. Proctor Foundation
University of California, San Francisco
ben.arnold@ucsf.edu

Abstract

Trachoma, caused by ocular *Chlamydia trachomatis* infection, is targeted for global elimination as a public health problem by 2030. To provide evidence for use of antibodies to monitor *C. trachomatis* transmission, we collated IgG responses to Pgp3 antigen, PCR positivity, and clinical observations from 19,811 children aged 1–9 years in 14 populations. We demonstrate that age-seroprevalence curves consistently shift along a gradient of transmission intensity: rising steeply in populations with high levels of infection and active trachoma and becoming flat in populations near elimination. Seroprevalence (range: 0–54%) and seroconversion rates (range: 0–15 per 100 person-years) correlate with PCR prevalence (r: 0.88, 95% CI: 0.77, 0.93). A seroprevalence threshold of 13.5% (seroconversion rate 2.75 per 100 person-years) identifies clusters with any infection at high sensitivity (>90%) and moderate specificity (69-75%). Antibody responses in young children provide a robust, generalizable approach to monitor population progress toward and beyond trachoma elimination.

Introduction

Trachoma is the leading infectious cause of blindness and has been targeted for elimination as a public health problem by 2030.[1] Caused by repeated infections with the bacterium *Chlamydia trachomatis* (*Ct*), trachoma has historically been monitored via district-level estimates of clinical signs.[2] However, clinical signs may not align well with transmission intensity, particularly after mass drug administration of azithromycin (MDA) [3–5], and are prone to measurement error, especially as cases become rare.[6–8] As a result, there has been growing interest in IgG antibody responses as an objective and easy-to-collect biomarker to inform control programs. Based on examples from other infectious diseases including malaria [9] and SARS-CoV-2,[10] use cases for trachoma serology may include monitoring population-level transmission to determine appropriate interventions, post-validation surveillance, opportunistic investigation of populations using blood collected for other purposes, and fine-scale geographic targeting of control measures.[11–13]

IgG antibody responses to *Ct* antigens Pgp3 and CT694 are sensitive and specific markers of *Ct* infection.[14,15] Assays have demonstrated consistency across platforms (multiplex bead, enzyme-linked immunosorbent, lateral flow),[16,17] robust seropositivity cutoffs,[18] and high repeatability.[19] Of the two antigens, Pgp3 appears to elicit a stronger and more durable response and is collected in most trachoma serology surveys.[20] In epidemiologic studies, investigators have observed alignment between population-level summaries of antibody response and other trachoma markers, including the presence of *Ct* DNA, as determined by PCR, and the active trachoma sign trachomatous inflammation—follicular (TF). Individual studies suggest age-dependent

seroprevalence curves rise steeply with age among children in trachoma-endemic

communities [14,15] and are flat in communities that have eliminated trachoma.[21–23] IgG

responses to Pgp3 can be measured from dried blood spots and have the potential to

be scaled through integration in multiplex surveillance strategies with other infectious

pathogens.[24] Key next steps to advance the use of serology to monitor trachoma

programs are to benchmark serology against independent measures of transmission,

notably PCR, and to formalize the analytic approaches used to summarize trachoma

antibody data.

Here, we collated IgG antibody, infection, and clinical data from 14 populations in

five countries across a gradient of trachoma transmission intensities that ranged from

hyper-endemic to post-elimination. Due to the shortcomings of clinical signs, we used

PCR as the primary marker of trachoma activity, with TF as a secondary indicator to

contextualize serological estimates. We hypothesized that population-level summaries

of trachoma antibody measurements would follow a consistent path toward elimination,

characterized by flattening of age-seroprevalence curves and a corresponding decline

in seroconversion rates. We also hypothesized that different seroepidemiologic

summary measures (e.g. seroprevalence, seroconversion rates) would be consistent

with one another and align similarly with population-level transmission. We completed a

series of analyses to test these hypotheses and in doing so, develop robust analytic

methods for trachoma serology as we approach the elimination endgame.

Results

Study populations and settings

We compiled serological, molecular, and clinical measurements collected between 2012 and 2019 across nine studies in five countries (**Supplementary Table 1**) [4,25–32]. When possible, measurements within the same study were stratified into populations corresponding to trachoma evaluation units, resulting in 14 study populations. All studies were conducted in Africa and represented a gradient of trachoma transmission from hyper-endemic transmission to post-elimination. Measurements were taken at a single time point or annually with the exception of Dosso, Niger, where visits occurred every six months for the first year and annually thereafter. Due to changing transmission and/or interventions over time in some studies, analyses included only the most recent round of measurements for each population. We analyzed sampling clusters with 15 or more serological measurements, a total of 459 clusters. The median number of children contributing information per cluster was 40 (interquartile range: 32–48) (**Supplementary Fig. 1**), for a total of 19,811 serological measurements. Eleven studies included children aged 1–9 years, and three studies focused on children aged 1–5 years (**Supplementary Fig. 2**).

We generated population-level summaries using the median and range across clusters and observed wide variation in seroprevalence (median: 7%; range: 0–54%), PCR prevalence (median: 3%; range: 0–26%), and TF prevalence (median: 6%; range: 0–56%) (**Fig. 1**). PCR, a measure of current infection, may disappear rapidly following MDA [33]. Among clusters with MDA in the past year, the median PCR prevalence was 0%, while among clusters without recent MDA, PCR prevalence was 12%. Cluster-level

estimates within the same population were often variable, likely a combination of

heterogeneity in disease transmission and stochasticity due to smaller sample sizes.

Across the gradient of transmission intensities, population-level summaries of

seroprevalence aligned with PCR and TF prevalence (**Fig. 1**).

Charting progress toward elimination using age-structured seroprevalence and

seroconversion rates

We estimated age-dependent seroprevalence curves using semiparametric

splines and seroconversion rates from age-structured seroprevalence (Methods).

Across populations, seroconversion rates ranged from 0 to 15 per 100 person-years

(median: 1.7) using a catalytic model without seroreversion (**Fig. 2**). Consistent with our

hypothesis, we observed that age-seroprevalence curves were flatter and

seroconversion rates were lower in areas with lower PCR prevalence. Age-

seroprevalence curves rose steeply in settings with high levels of infection such as Wag

Hemra and Andabet, Ethiopia, reaching >50% seroprevalence by age 9 years. In

contrast, in populations with flatter curves (<10% seroprevalence by age 9 years,

seroconversion rate <1 per 100 person-years), PCR prevalence was 0% when

measured (Woreta town and Alefa, Ethiopia). Among populations with moderately

increasing age-seroprevalence curves, roughly corresponding to seroconversion rates

between 1 and 5 per 100 person-years, PCR prevalence ranged from 0 (Dera, Ethiopia)

to 1.9% (Kongwa, Tanzania 2018).

Agreement between serology-based summary measures

Summary statistics estimated from age-seroprevalence curves provide

additional, useful summary measures of transmission.[9,34] Population-level summaries of

IgG responses include geometric mean IgG levels, seroprevalence, and seroconversion

rates — each progression from IgG levels to seroconversion rates relies on additional

model assumptions and analysis complexity (details in Methods). In the estimation of

seroconversion rates from age-structured seroprevalence, we considered a range of

model complexity that included a catalytic model (corresponding to a susceptible-

infected-recovered, SIR, model), a reversible catalytic model allowing for seroreversion

(corresponding to a susceptible-infected-susceptible, SIS, model), and a

semiparametric hazard model that allowed for age-varying seroconversion rates.

A key question for elimination programs is whether the additional complexity in

analysis leads to more useful information for identifying populations with ongoing ocular

Ct transmission. We estimated each summary at the sampling cluster and population

levels across the 14 study populations and found high correlation between all measures

(Spearman ρ ≥0.88 for all comparisons, **Fig. 3**). Cluster-level seroprevalence was

strongly, linearly related with geometric mean IgG levels on the $\log_{10}$ scale (**Fig. 3a**),

and there was a strong, non-linear relationship between seroprevalence and the

seroconversion rate (**Fig. 3b**). Catalytic models that allowed for seroreversion shifted

seroconversion rates up, particularly for clusters with a seroconversion rate greater than

20 per 100 person-years but had minimal influence on estimates at intermediate and

lower levels of transmission (**Fig. 3c**). Similarly, seroprevalence was tightly linked with

seroconversion rates that allowed for seroreversion in settings with lower prevalence,

and greater dispersion was observed in hyperendemic populations (**Fig. 3d**). The most

complex model, a semiparametric proportional hazards spline model that allowed for an

age-varying seroconversion rate, required more data than would be typically available at

the sampling cluster level and thus could only be estimated at the population level

where its estimates aligned closely with a simpler, constant rate model (**Supplementary**

Fig. 3). These results show that all serologic summary measures provide similar

information when averaged at the cluster or population level across all ranges of

transmission and particularly at lower levels of transmission.

Comparing trachoma indicators in the presence and absence of MDA

184   As most trachoma program interventions act to clear infection or reduce its

transmission, we sought summaries that could capture variation in populations' *Ct*

infection burden. Seroprevalence and PCR prevalence aligned closely at the population

level (r = 0.88; 95% CI: 0.77–0.93, **Fig. 4a**). At both the cluster- and population-levels,

seroprevalence was almost always greater than or equal to PCR prevalence,

underscoring the sensitivity of seroprevalence as a measure of current or past infection.

However, PCR prevalence was highly variable across levels of seroprevalence; low

PCR prevalence in the context of high seroprevalence may imply previously high levels

of infection that had been controlled by MDA or other interventions. Relationships

between TF and PCR prevalence were similar (population-level r = 0.92; 95% CI: 0.73–

0.96, **Fig. 4b**).

195   As shown in prior work,[35] TF and seroprevalence were more strongly correlated

with PCR prevalence in the absence of MDA in the past year (**Fig. 4a, 4b**). In the

absence of MDA, the relationship between seroprevalence and PCR prevalence was

nearly linear, particularly in high transmission settings. In the presence of recent MDA,

correlations between trachoma indicators weakened presumably because IgG and TF

prevalence remain elevated as durable indicators of trachoma even after infections

have been reduced through MDA.

We also stratified the analyses by child age and observed similar correlations

between indicators among children aged 1–9 years compared to children aged 1–5

years (**Fig. 5**). When summarizing IgG responses as seroconversion rate instead of

seroprevalence, overall results and subgroup results by recent MDA and age group

were similar (**Supplementary Fig. 4**), reflecting the tight correlation between serologic

summaries (**Fig. 3**). Our results show that serologic summaries align with PCR

prevalence as well or better than TF, the current programmatic indicator, and that

serology performs well even among preschool aged children. In populations that have

recently undergone MDA, IgG and TF will likely remain elevated even as infection

prevalence falls.

Assessing serologic thresholds for elimination of infections

Due to the wide variability in trachoma indicators both within and between

populations, we used a nonparametric approach to evaluate potential serologic

summary thresholds. Based on the alignment between seroprevalence and PCR at the

cluster level and the relatively large number of clusters, we assessed sensitivity and

specificity using cluster-level values. At each potential threshold, sensitivity and

specificity were calculated across the 281 clusters with PCR measurements, 99 of

which had at least one infection detected by PCR. Although presence of a single

infection is a stringent threshold, an appropriate level of PCR prevalence required to

prevent blindness due to trachoma has yet to be established. Under this definition, a

threshold with high sensitivity would result in more infected clusters being detected,

while a threshold with high specificity might imply less unnecessary intervention. While

overtreatment should be avoided, we focused on thresholds with high sensitivity with

the goal of elimination in mind.

There was good classification of clusters with and without Ct infections based on

either seroprevalence or seroconversion rates (AUC=0.92). Thresholds of 13.5%

seroprevalence (**Fig. 6, Supplementary Table 2**) or 2.75 seroconversions per 100

person-years (**Supplementary Fig. 5, Supplementary Table 3**) had 90% sensitivity

and 69-75% specificity to identify clusters with any PCR-detected infections. Thresholds

of 22.5% seroprevalence and 5.75 seroconversions per 100 person-years had 80%

sensitivity and 92-93% specificity. Thresholds were conservative when compared

against population-specific sensitivity estimates in high transmission settings, but

sensitivity dropped quickly in populations with very few infected clusters (n=4 in

Chikwawa, Malawi and n=6 in Mchinji, Malawi) (**Fig. 6a**).

The overall analysis included all clusters regardless of age group. In a sensitivity

analysis that included only children aged 1–5 years, classification of clusters with and

without *Ct* infections was almost identical to the main analysis (AUC=0.92), and

thresholds of 12.5% seroprevalence and 2.75 conversions per 100 person-years had

90% sensitivity and 69-71% specificity to identify clusters with any PCR-detected

infections (**Supplementary Fig 6, Supplementary Table 4, Supplementary Table 5**).

In a supplementary assessment of the thresholds, we applied them to

populations with very low trachoma prevalence that were not included in the threshold

analysis because cluster-level PCR results were unavailable (Dosso, Alefa, and Woreta

town, see **Figs. 1** and **2**). District-level PCR from Alefa and Woreta town were estimated

to be 0%, and a recent study from the same population in Dosso found no *Ct* in pooled

metagenomic testing of ocular swabs.[36] In these three populations, 98% of clusters

(60/61) fell below the serologic thresholds for 90% sensitivity, supporting the

interpretation of low levels of infection below the estimated thresholds.

Discussion

Using antibody measurements from 14 populations across a gradient of *Ct*

transmission intensity, we demonstrated that IgG Pgp3 age-seroprevalence curves

flatten and seroprevalence and seroconversion rates progress toward zero as

populations approach elimination, consistent with biological assumptions and

observations across other pathogens.[34,37] To our knowledge, this is the largest synthesis

of *Ct* serology and infection data spanning globally relevant transmission settings from

hyper-endemic to elimination. Summaries of IgG responses to *Ct* antigen Pgp3 among

children aged 1–9 years aligned similarly with PCR prevalence and with one another at

both the cluster- and population-levels, indicating that cluster-level Pgp3 summaries

reflect variation in *Ct* infections and ongoing transmission. Combining information

across all populations, we found that thresholds of 13.5% seroprevalence and 2.75

seroconversions per 100 person-years identified clusters with any infection with high

sensitivity (>90%) and moderate specificity (69 to 75%). We observed similar results

when analyses were restricted to children aged 1–5 years, an age group that is

potentially easier to sample in household surveys as they are not yet in school.

We demonstrated that seroprevalence and seroconversion rates perform as well

or better as correlates of population levels of infection compared with clinical TF, and

serology is arguably more objective, granular, and scalable for surveillance. Although

clinical signs are important markers of disease progression, MDA is targeted towards *Ct*

infections — if clinical signs continue to be present in the absence of antibody

responses, further investigation may be warranted to determine other potential causes

of inflammation. Compared to PCR, which also measures *Ct* infections, serology is cost-

effective, with simpler collection procedures and the opportunity to leverage banked

samples, and measures exposure over time versus at a single point, an advantage in

low prevalence settings.

By focusing on parsimonious, generalizable methods, our aim was to present

seroepidemiologic approaches that could be easily applied and interpreted by trachoma

control programs. Trachoma programs currently rely on district-level estimates of active

trachoma, and this analysis may be extended to develop district-level thresholds as an

increasing number of district-level, population-based serological surveys become

available. Cluster-level estimates, as investigated here, may be a promising alternative

to identify focal areas for intervention, particularly in combination with geostatistical

methods to improve precision and project across unsurveyed regions.[38]

Programmatic decisions related to suspension or reinitiation of antibiotic MDA

primarily take place in low to intermediate transmission settings, and this study

demonstrates that the information serologic surveillance provides in such settings

should be robust to choice of summary statistic. Serological summaries of increasing

complexity were tightly correlated with one another, and the relationship was nearly

linear in settings with low to intermediate transmission (**Fig. 3**). Quantitative IgG

responses potentially provide information at very low levels of *Ct* transmission when

most children are seronegative,[39] but a challenge is that IgG responses are in arbitrary

units that may not be directly comparable across studies. Members of our team are

developing a chimeric, monoclonal antibody to help facilitate direct comparison of

quantitative antibody levels across studies.[12] Seroprevalence and seroconversion rates

are standard transformations of the quantitative IgG response that are easier to

compare across studies and labs. A potential drawback of seroprevalence and

seroconversion is that they may be sensitive to choice of the seropositivity cutoff,

potentially affecting programmatic decisions based on thresholds. In a sensitivity

analysis, we found that identification of clusters with *Ct* infection based on

seroprevalence and seroconversion rates were robust to large changes in the

seropositivity cutoff (**Supplementary Fig 7**). The seroconversion rate is tightly linked to

the slope of the age-seroprevalence curve (details in Methods). Additionally, the

seroconversion rate implicitly adjusts for age (not guaranteed with mean IgG or

seroprevalence) and can be interpreted as a measure of a pathogen's force of infection.

Although we did not consider complicated seroconversion models that allowed for

changes in transmission over time, such complexity may be less relevant when

analyzing measurements from young children because their antibody responses reflect

recent infections.[40–42] Our results support estimation of age-seroprevalence curves

among young children combined with estimation of seroconversion rates using a simple,

single-rate model to characterize trachoma transmission. Our findings demonstrate that

the slope of the age-seroprevalence curve and the seroconversion rate are sensitive

and moderately specific markers of population-level *Ct* infection. Seroprevalence is

another simple, robust summary measure that aligned with infections as well as

seroconversion rate, particularly in the absence of recent MDA, but care should be

taken to ensure similar age structure between populations to avoid bias.

We found that serologic summaries were sensitive indicators of *Ct* infection but

have only moderate specificity: antibody responses were nearly always present in

populations with infections, but the IgG signal persisted even if recent MDA reduced

infection to low levels. This pattern suggests that populations requiring treatment will

rarely be missed by serology but further verification with PCR could prevent

overtreatment in the case of false positives. Because IgG responses to Pgp3 are

durable, age-seroprevalence curves and statistics estimated from them may reflect

historical transmission patterns and remain high despite low levels of infection resulting

from control measures or secular trends. Restricting analysis to younger children (e.g.,

children born after discontinuing antibiotic MDA) or carefully accounting for past MDA

treatments in the interpretation of antibody data may decrease false positives detected

by IgG. At the cluster level, infections may also be missed due to small sample sizes.

Extending this work using a freedom-from-infection framework may inform appropriate

cluster-level sample sizes for a desired level of uncertainty.[43]

Here, we focused on IgG among young children and its relationship with *Ct*

infection to extend a previous study that combined nine trachoma serology surveys and

compared IgG seroconversion rates with clinical indicators among people of all ages.[40]

A focus on young children rather than all ages enabled us to simplify the modeling

approach used to estimate seroconversion rates under the assumption that

transmission was approximately stable over the age range. We focused on the

relationship between serology and PCR infection to assess the utility of serology to

monitor differences in pathogen transmission. The earlier synthesis compared indicators

at the district level, which is the current scale of decision making for elimination

programs. A caveat of the approach used in this study to identify serology thresholds to

identify the presence of *Ct* infections is that we used clusters as the unit of analysis — a

much finer spatial scale than district. We felt a similar, non-parametric threshold

analysis at the district (study) level would not be informative with only 11 studies that

included *Ct* infection measurements (**Fig. 1**), versus 281 unique clusters (**Fig. 6**). Future

estimates of district-level serology thresholds for elimination, using the same summary

statistics but potentially using a different approach to identify thresholds, would be a

useful extension.

This work is subject to limitations. First, the data we analyzed were compiled

from different previously published studies and sites that were available to us. Our

results may not be representative of all populations with ongoing trachoma

transmission. For example, the included studies come from five countries in Africa, but

trachoma continues to be endemic in the other regions of Africa, Latin America, Asia,

and the Pacific Islands.[44] As a secondary analysis, our work was also affected by design

features of individual studies, such as site selection in RCTs, which were typically not

selected using probability samples. Second, all models used to estimate

seroconversion, except for the semiparametric spline model, assumed homogeneity of

seroconversion rate over age and time. For most studies, we expected stable

transmission among 1–9-year-olds in the recent past. Our analysis used an estimate of

seroreversion from one longitudinal cohort,[45] but data beyond this cohort is limited;

however, based on a sensitivity analysis, no single seroreversion value resulted in the

best model fit across populations (**Supplementary Fig. 8**). Finally, we were unable to

evaluate more specific subgroups, such as populations with different MDA histories or

populations experiencing recrudescence, due to limited data. Based on the variability

observed between populations, refinement of thresholds may be warranted as more

data are collected.

In conclusion, IgG responses to *Ct* antigen Pgp3 among 1–9-year-olds aligned

closely with ongoing transmission as measured by PCR and TF across a range of

trachoma endemicity settings. Consistent with patterns observed across other

pathogens, age-dependent Pgp3 seroprevalence curves became flatter and

seroconversion rates declined to zero as populations approached elimination —

providing a coherent framework for monitoring *Ct* transmission in seroepidemiologic

studies. Serologic summaries estimated via a range of model complexity were sensitive

markers of ocular chlamydial infection and were consistent with one another, implying

that simpler approaches are likely sufficient to capture variation in transmission. These

results support use of serologic surveys to inform trachoma programs as populations

approach elimination.

Methods

Contributing studies

We gathered data from published trachoma serology surveys, with an emphasis on IgG antibody responses to Pgp3 collected among children aged 1–9 years and relatively recent reports (**Supplementary Table 1**). All studies were conducted between 2012 and 2019. Children below the age of 1 year were excluded to mitigate the influence of maternal antibodies. Based on the original study designs, measurements in Matameye, Niger (PRET) and Wag Hemra, Ethiopia (TAITU) were restricted to children aged under 6 years; in Dosso, Niger (MORDOR), the study was limited to children aged under 5 years; and in Alefa, Andabet, Dera, and Woreta town, Ethiopia, infections were measured among children aged 1–5-years, while serology and TF were measured among children aged 1–9-year. For measurements collected as part of a population-based surveys, multi-level cluster random sampling was used. For measurements collected as part of a randomized controlled trial, we combined data across arms unless otherwise noted (e.g., stratification by recent MDA). Due to changing transmission and/or control interventions in studies with repeated cross-sectional data (WUHA in Wag Hemra, Ethiopia; Kongwa, Tanzania from 2012-2015; MORDOR in Dosso, Niger), we included only the most recent year of measurements with serology, and PCR measurements if available, for each population. We excluded clusters with fewer than 15 children measured to ensure sufficient information to estimate cluster level means (n=22 clusters excluded, reduced from 481 to 459).

Details of serological, clinical, and PCR measurements can be found in the published reports for each study [4,25–32]. In all but one study, dried blood spots were

analyzed for IgG antibodies to Pgp3 using a multiplex bead assay on a Luminex

platform and were reported as median fluorescence intensity minus background (MFI-

bg), and seropositivity cutoffs were generated using receiver operator characteristic

(ROC) methods [14]. In Malawi, dried blood spots were tested for IgG antibodies against

Pgp3 using ELISA, and the seropositivity cutoff was determined based on a finite

mixture model [31]. ELISA-based population-level measurements of Pgp3 have been

shown to have good agreement with multiplex bead assays [46]. We used cutoffs defined

by each study to assign seropositivity status. To assess robustness to seropositivity

cutoffs, we compared seroprevalence and seroconversion rate calculated across a

range of arbitrary cutoffs for four study populations at different levels of trachoma

prevalence (**Supplementary Fig. 7**). Clinical disease was assessed by trained field

graders according to the WHO simplified grading system [47], which defines TF as the

presence of five or more follicles which are (a) at least 0.5 mm in diameter and (b)

located in the central part of the upper tarsal conjunctiva. Conjunctival swabs were

assessed for *Ct* DNA using PCR. In 5 out of 7 studies with PCR measurements, cluster-

level prevalence was estimated from individual-level results [29–31,48,49]; in one study

(PRET), cluster-level prevalence was estimated from pooled results using maximum

likelihood methods [50,51]. For Andabet, Dera, Woreta town, and Alefa, Ethiopia, *Ct*

infection prevalence was estimated at the district level from pooled results using

maximum likelihood methods [26].

Cluster-level prevalence was calculated as the number of children who were

sero-, PCR- or TF-positive divided by the number of children tested for the respective

outcome. When possible, "populations" were defined by districts or evaluation units

currently used for trachoma monitoring. Population-level prevalence estimates were

defined as the median value across clusters. Age-seroprevalence curves were

estimated by pooling all measurements at the population level, calculating

seroprevalence for one-year age groups, and fitting cubic spline models to generate

smooth trend lines.

Estimating serology-based summary measures

We summarized IgG responses as geometric mean IgG levels, seroprevalence,

and seroconversion rates from several models. The seroconversion rate from a current

status, single-rate catalytic model assuming no seroreversion is closely tied to the slope

of age-seroprevalence curve.[52] Specifically, the hazard (seroconversion rate) is equal to

the slope of the age-seroprevalence curve divided by the complement of the

seroprevalence at age a. It can be shown that the seroconversion rate based on this

model can be estimated as the exponentiated intercept from a generalized linear model

with binomial error structure and a complementary log-log link: [53]

441
$$\log\big[-\log\big(1 - P(Y = 1 \mid A)\big)\big] = \log(\lambda) + \log(A)$$

where Y represents individual level serostatus (1: seropositive, 0: seronegative or

equivocal), A is the child's age in years, and λ is the seroconversion rate. The

seroconversion rate provides an estimate of the force of infection, an epidemiological

parameter that denotes the rate at which susceptible individuals in the population

become infected.

Next, we extended this model to allow for seroreversion. Cross-sectional data do

not contain sufficient information to reliably estimate both seroreversion and

seroconversion rates.[54] Therefore, we fit a binomial maximum likelihood model for

seroconversion with fixed seroreversion rates ranging from 0.02 to 0.20 per person-

year:[21,26,40]

$$P(Y = 1 \mid A) = \frac{\lambda}{\lambda + \rho}[1 - \exp(-(\lambda + \rho) \times A)]$$

where ρ is the assumed seroreversion rate. In our main analyses, we assumed a

seroreversion rate of 6.6 per 100 person-years based on a longitudinal cohort in

Kongwa, Tanzania monitored in the absence of MDA [45], which is likely conservative for

higher transmission settings. No level of seroreversion consistently provided the best fit

across populations (**Supplementary Fig. 8**). This model did not converge in several

clusters (6 out of 416 clusters with seroprevalence >0%, or 1.4%), which often

contained few seropositive children.

Finally, we fit semiparametric spline models to allow seroconversion to vary by

age.[52] We fit this model only at the population level, as it requires more data than are

typically available at the sampling cluster level (around 20-40 children). We fit a

generalized linear model with complementary log-log link for seropositivity:

$$\log[-\log(1 - P(Y = 1 \mid A))] = g(A)$$

465 where *g(A)* is a flexible function for age modeled using cubic splines. To estimate the

466 average seroconversion rate in each population, λ, we integrated over age using

467 predictions from the model. We used the relationship between the hazard $\lambda(a)$ and

468 cumulative incidence $F(a)$, where $F(a)$ is the predicted seroprevalence at age a (details

469 in [37]).

$$\lambda = \int_{a_1}^{a_2} \lambda(a)da = \frac{\log[1 - F(a_1)] - \log[1 - F(a_2)]}{a_2 - a_1}$$

Comparison of different trachoma indicators

We used the Pearson correlation coefficient to compare serologic summaries

and TF prevalence with PCR prevalence at the population and cluster levels. We

conducted this analysis across all populations with PCR measurements and explored

the impact of contextual factors by stratifying clusters into subgroups defined by MDA in

the past year (yes / no) and age range (1–9-year-olds / 1–5-year-olds).

We used the Spearman rank correlation coefficient to compare different serologic

summaries with one another at the cluster level, allowing for non-linearity in the

relationships. We estimated simultaneous confidence intervals from a cubic spline to

summarize the relationship between markers at the cluster level, including a random

effect for study to allow for correlated measures within-study.

Serologic thresholds for elimination

We used a non-parametric approach to assess thresholds of seroprevalence or

seroconversion rates to classify clusters without PCR infections. For overall estimates,

we combined clusters from all populations with PCR measurements, for a total of 281

clusters and 99 clusters with at least one PCR-detected infection. We defined a range of

cutoffs covering nearly all cluster-level estimates (0 to 100% for seroprevalence, 0 to 50

per 100 person-years for seroconversion rate) and divided the range into 200

increments. At each step, we calculated sensitivity as the proportion of clusters with

serology values above the threshold among clusters with any infection, and specificity

as the proportion of clusters with serology value less than or equal to the threshold

among clusters with zero infections detected. We identified the highest thresholds

achieving at least 90% and 80% sensitivity. We also presented these results as receiver

operating characteristic (ROC) curves and calculated overall area-under-the-curve

(AUC). We calculated sensitivity, specificity, and the ROC curve for each population

separately.

Data availability

R version 4.2.2 (2022-10-21, "Innocent and Trusting") was used for this

analysis.[55] De-identified data and all code to reproduce this work are publicly available

(*note: during peer review we are finalizing agreements to provide de-identified data*):

https://osf.io/e6j5a/ .

Acknowledgements

Ethics statement. The secondary analysis protocol was reviewed and approved

by the Institutional Review Board at the University of California, San Francisco (Protocol

#20-33198). All primary data that contributed to the analysis was collected after

obtaining informed consent from all participants or their guardians under separate

human subjects research protocols in accordance with the Declaration of Helsinki.

Conflict of interest statement. The authors have no conflicts of interest to report.

The authors alone are responsible for the views expressed in this article, and they do

not necessarily represent the views, decisions, or policies of the institutions with which

they are affiliated.

Funding statement. This work was supported by the National Institute of Allergy

and Infectious Diseases (R01-AI158884 to B.F.A.). AWS is a staff member of the World

Health Organization.

Disclaimer. The findings and conclusions in this article are those of the authors

and do not necessarily represent the official position of the National Institutes of Health

or the Centers for Disease Control and Prevention. Use of trade names is for

identification only and does not imply endorsement by the Public Health Service or by

the U.S. Department of Health and Human Services.

Author contributions ([CRediT taxonomy](#)).
Conceptualization: CT, AWS, DLM, SDN, PJL, BFA
Data curation: CT, DLM, BFA
Formal analysis: CT, BFA
Funding acquisition: BFA, DLM
Investigation: CT, BFA
Methodology: CT, BFA
Project administration: DLM, BFA
Resources: All authors
Software: CT, BFA
Supervision: AWS, DLM, SDN, SKW, TML, JDK, PJL
Validation: CT, BG, DLM, BFA
Visualization: CT, BFA
Writing - original draft preparation: CT, BFA
Writing - review & editing: All authors
540
541
542
543

References

1. World Health Organization. *Ending the neglect to attain the sustainable development goals: a roadmap for neglected tropical diseases 2021-2030.* https://apps.who.int/iris/handle/10665/361856 (2020).

2. Taylor, H. R., Burton, M. J., Haddad, D., West, S. & Wright, H. Trachoma. *The Lancet* **384**, 2142–2152 (2014).

3. Keenan, J. D. *et al.* Clinical Activity and Polymerase Chain Reaction Evidence of Chlamydial Infection after Repeated Mass Antibiotic Treatments for Trachoma. *Am. J. Trop. Med. Hyg.* **82**, 482–487 (2010).

4. Amza, A. *et al.* Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger. *Ophthalmic Epidemiol.* **26**, 231–237 (2019).

5. Ramadhani, A. M., Derrick, T., Macleod, D., Holland, M. J. & Burton, M. J. The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment. *PLoS Negl. Trop. Dis.* **10**, e0005080 (2016).

6. Assaad, F. A. & Maxwell-Lyons, F. Systematic observer variation in trachoma studies. *Bull. World Health Organ.* **36**, 885–900 (1967).

7. Tielsch, J. M. *et al.* Trachoma grading: observer trials conducted in southern Malawi. *Br. J. Ophthalmol.* **71**, 371–374 (1987).

8. Gebresillasie, S. *et al.* Inter-Rater Agreement between Trachoma Graders: Comparison of Grades Given in Field Conditions versus Grades from Photographic Review. *Ophthalmic Epidemiol.* **22**, 162–169 (2015).

9. Corran, P., Coleman, P., Riley, E. & Drakeley, C. Serology: a robust indicator of malaria transmission intensity? *Trends Parasitol.* **23**, 575–582 (2007).

10. Stringhini, S. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet Lond. Engl.* **396**, 313–319 (2020).

11. Woodhall, S. C. *et al.* Advancing the public health applications of Chlamydia trachomatis serology. *Lancet Infect. Dis.* **18**, e399–e407 (2018).

12. Martin, D. L. *et al.* The use of serology for trachoma surveillance: Current status and priorities for future investigation. *PLoS Negl. Trop. Dis.* **14**, e0008316 (2020).

13. Cooley, G. M. *et al.* No Serological Evidence of Trachoma or Yaws Among Residents of Registered Camps and Makeshift Settlements in Cox's Bazar, Bangladesh. *Am. J. Trop. Med. Hyg.* **104**, 2031–2037 (2021).

14. Goodhew, E. B. *et al.* CT694 and pgp3 as Serological Tools for Monitoring Trachoma Programs. *PLoS Negl. Trop. Dis.* **6**, e1873 (2012).

15. Goodhew, E. B. *et al.* Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration. *BMC Infect. Dis.* **14**, 3154 (2014).

16. Gwyn, S. *et al.* Comparison of Platforms for Testing Antibody Responses against the Chlamydia trachomatis Antigen Pgp3. *Am. J. Trop. Med. Hyg.* **97**, 1662–1668 (2017).

17. Wiegand, R. E. *et al.* Latent class modeling to compare testing platforms for detection of antibodies against the Chlamydia trachomatis antigen Pgp3. *Sci. Rep.* **8**, 4232 (2018).

18. Migchelsen, S. J. *et al.* Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies. *PLoS Negl. Trop. Dis.* **11**, e0005230 (2017).

19. Kaur, H., Dize, L., Munoz, B., Gaydos, C. & West, S. K. Evaluation of the reproducibility of a serological test for antibodies to Chlamydia trachomatis pgp3: A potential surveillance tool for trachoma programs. *J. Microbiol. Methods* **147**, 56–58 (2018).

20. Wang, J. *et al.* A Genome-Wide Profiling of the Humoral Immune Response to Chlamydia
trachomatis Infection Reveals Vaccine Candidate Antigens Expressed in Humans. *J.*
Immunol. **185**, 1670–1680 (2010).
21. Martin, D. L. *et al.* Serology for Trachoma Surveillance after Cessation of Mass Drug
Administration. *PLoS Negl. Trop. Dis.* **9**, e0003555 (2015).
22. Pant, B. P. *et al.* Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study
from the Nepal National Trachoma Program. *PLoS Negl. Trop. Dis.* **10**, e0004462 (2016).
23. West, S. K. *et al.* Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool
for National Trachoma Control Programs? Results from a District Survey. *PLoS Negl. Trop.*
Dis. **10**, e0004352 (2016).
24. Arnold, B. F., Scobie, H. M., Priest, J. W. & Lammie, P. J. Integrated Serologic Surveillance
of Population Immunity and Disease Transmission. *Emerg. Infect. Dis.* **24**, 1188–1194
(2018).
25. Kim, J. S. *et al.* Community-level chlamydial serology for assessing trachoma elimination in
trachoma-endemic Niger. *PLoS Negl. Trop. Dis.* **13**, (2019).
26. Nash, S. D. *et al.* Population-Based Prevalence of Chlamydia trachomatis Infection and
Antibodies in four Districts with Varying Levels of Trachoma Endemicity in Amhara, Ethiopia.
Am. J. Trop. Med. Hyg. (2020) doi:10.4269/ajtmh.20-0777.
27. Wittberg, D. M. *et al.* WASH Upgrades for Health in Amhara (WUHA): study protocol for a
cluster-randomised trial in Ethiopia. *BMJ Open* **11**, e039529 (2021).
28. Keenan, J. D. *et al.* Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. *N.*
Engl. J. Med. **378**, 1583–1592 (2018).
29. Wilson, N. *et al.* Evaluation of a Single Dose of Azithromycin for Trachoma in Low-
Prevalence Communities. *Ophthalmic Epidemiol.* **26**, 1–6 (2019).
30. Odonkor, M. *et al.* Serology, infection, and clinical trachoma as tools in prevalence surveys
for re-emergence of trachoma in a formerly hyperendemic district. *PLoS Negl. Trop. Dis.* **15**,
e0009343 (2021).
31. Burr, S. E. *et al.* Pgp3 seroprevalence and associations with active trachoma and ocular
Chlamydia trachomatis infection in Malawi: cross-sectional surveys in six evaluation units.
PLoS Negl. Trop. Dis. **13**, e0007749 (2019).
32. Hammou, J. *et al.* Post-Validation Survey in Two Districts of Morocco after the Elimination of
Trachoma as a Public Health Problem. *Am. J. Trop. Med. Hyg.* **106**, 1370–1378 (2022).
33. Solomon, A. W. *et al.* Trachoma. *Nat. Rev. Dis. Primer* **8**, 1–20 (2022).
34. Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases,
malaria, and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.* **11**,
e0005616 (2017).
35. Tedijanto, C. *et al.* Predicting future community-level ocular Chlamydia trachomatis infection
prevalence using serological, clinical, molecular, and geospatial data. *PLoS Negl. Trop. Dis.*
16, e0010273 (2022).
36. Arzika, A. M. *et al.* Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged
Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial. *JAMA*
Netw. Open **5**, e2228244 (2022).
37. Arnold, B. F. *et al.* Fine-scale heterogeneity in *Schistosoma mansoni* force of infection
measured through antibody response. *Proc. Natl. Acad. Sci.* **117**, 23174–23181 (2020).
38. Amoah, B. *et al.* Model-based geostatistics enables more precise estimates of neglected
tropical-disease prevalence in elimination settings: mapping trachoma prevalence in
Ethiopia. *Int. J. Epidemiol.* **51**, 468–478 (2022).
39. Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases,
malaria, and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.* **11**,
e0005616 (2017).

40. Pinsent, A. *et al.* The utility of serology for elimination surveillance of trachoma. *Nat.*
643   *Commun.* **9**, 5444 (2018).
644 41. Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance of
645   malaria transmission intensity. *Sci. Rep.* **6**, 19472 (2016).
646 42. Sepúlveda, N., Stresman, G., White, M. T. & Drakeley, C. J. Current Mathematical Models
647   for Analyzing Anti-Malarial Antibody Data with an Eye to Malaria Elimination and
648   Eradication. *J. Immunol. Res.* **2015**, 1–21 (2015).
649 43. Michael, E. *et al.* Substantiating freedom from parasitic infection by combining transmission
650   model predictions with disease surveys. *Nat. Commun.* **9**, 4324 (2018).
651 44. Renneker, K. K. *et al.* Global progress toward the elimination of active trachoma: an
652   analysis of 38 countries. *Lancet Glob. Health* **10**, e491–e500 (2022).
653 45. West, S. K. *et al.* Longitudinal change in the serology of antibodies to Chlamydia
654   trachomatis pgp3 in children residing in a trachoma area. *Sci. Rep.* **8**, 3520 (2018).
655 46. Gwyn, S. *et al.* The Performance of Immunoassays to Measure Antibodies to the Chlamydia
656   trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma. *Am. J. Trop.*
657   *Med. Hyg.* (2021) doi:10.4269/ajtmh.21-0541.
658 47. Thylefors, B., Dawson, C. R., Jones, B. R., West, S. K. & Taylor, H. R. A simple system for
659   the assessment of trachoma and its complications. *Bull. World Health Organ.* **65**, 477–483
660   (1987).
661 48. Melo, J. S. *et al.* Targeted antibiotics for trachoma: a cluster-randomized trial. *Clin. Infect.*
662   *Dis.* ciab193 (2021) doi:10.1093/cid/ciab193.
663 49. Aragie, S. *et al.* Water, sanitation, and hygiene for control of trachoma in Ethiopia (WUHA):
664   a two-arm, parallel-group, cluster-randomised trial. *Lancet Glob. Health* **10**, e87–e95 (2022).
665 50. Ray, K. J. *et al.* Estimating Community Prevalence of Ocular *Chlamydia trachomatis*
666   Infection using Pooled Polymerase Chain Reaction Testing. *Ophthalmic Epidemiol.* **21**, 86–
667   91 (2014).
668 51. Amza, A. *et al.* A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma
669   Treatment to Children. *Clin. Infect. Dis.* **64**, 743–750 (2017).
670 52. Hens, N., Shkedy, Z., Aerts, M., Damme, C. F. P. V. & Beutels, P. *Modeling Infectious*
671   *Disease Parameters Based on Serological and Social Contact Data.* (Springer, 2012).
672 53. Jewell, N. P. & Laan, M. V. Generalizations of current status data with applications. *Lifetime*
673   *Data Anal.* **1**, 101–109 (1995).
674 54. Arnold, B. F. *et al.* Enteropathogen antibody dynamics and force of infection among children
675   in low-resource settings. *eLife* **8**, e45594 (2019).
676 55. R Core Team. *R: A language and environment for statistical computing.* (R Foundation for
677   Statistical Computing, 2020).
678 56. Hammou, J. *et al.* In Morocco, the elimination of trachoma as a public health problem
679   becomes a reality. *Lancet Glob. Health* **5**, e250–e251 (2017).
680

Abbreviations: n = number of individuals measured; m = number of clusters
* Estimates collected in population-based prevalence survey
† Serology, PCR, and TF measured among 1–5-year-olds
‡ PCR prevalence estimated only at district-level among 1–5-year-olds

Figure 1. Seroprevalence, PCR positivity, and TF prevalence across study populations. Cluster-level prevalence estimates are represented by colored lines, and overlaid boxplots show the median, interquartile range, and range (excluding outliers defined as points more than 1.5 times the interquartile range from the 25th or 75th percentile) for each population. Study site, country, study name (if applicable), and year of data collection are listed on the left with number of individuals (n) and number of clusters (m) included in the analyses. For studies with only district-level estimates of PCR prevalence the mean is indicated with a circle rather than box plot. NA marks studies that did not measure PCR or trachomatous inflammation—follicular (TF). Study populations are arranged in descending order of seroconversion rates, presented in Figure 2.

Abbreviations: PY = person-years; ETH = Ethiopia; NER = Niger; TZA = Tanzania; MWI = Malawi; MAR = Morocco

Figure 2. Age-dependent seroprevalence curves, modeled seroconversion rates, and PCR prevalence across study populations. Cubic splines fit to seroprevalence by age are shown in the left plot. Cluster-level seroconversion rates and PCR prevalence estimates are represented by colored lines, and overlaid boxplots show the median, interquartile range, and range excluding outliers for each population. Study populations are arranged in descending order of median seroconversion rate assuming no seroreversion. *Ct* PCR measurements are identical to Figure 1 and are included for reference. For studies with only district-level estimates of PCR prevalence the mean is indicated with a circle rather than box plot. NA indicates that a study did not measure *Ct* infections with PCR.

Figure 3. Relationship between different cluster-level summaries including geometric mean IgG response, seroprevalence, and seroconversion rates with and without seroreversion. Spearman rank correlations across sampling clusters (a-d) are shown for each comparison. A fixed seroreversion rate of 6.6 per 100 person-years was assumed in the catalytic model allowing for seroreversion (Methods). Shaded bands show simultaneous 95% confidence intervals for a spline fit through cluster-level estimates. Abbreviations: PY = person-years; ETH = Ethiopia; MAR = Morocco; MWI = Malawi; NER = Niger; TZA = Tanzania.

Figure 4. Relationship between trachoma biomarkers in the presence and absence of recent mass drug administration (MDA). a Correlations between cluster PCR prevalence and seroprevalence overall and stratified by whether the study population had received MDA in the previous year. b Correlations between PCR prevalence and TF prevalence overall and stratified by whether the study population had received MDA in the previous year. In all panels, medians across clusters for each study population are represented by larger points with black outline. Each plot includes the identity line (dotted) and Pearson correlations at the cluster- and population-levels. 95% confidence intervals (CIs) are based on 1,000 bootstrapped samples, holding populations fixed and resampling clusters with replacement. Population-level values are included for Andabet, Dera, Woreta town, and Alefa, Ethiopia, but cluster-level values were not available for these populations. Abbreviations: ETH = Ethiopia; MWI = Malawi; NER = Niger; TZA = Tanzania.

Figure 5. Relationship between trachoma biomarkers in different monitoring age ranges.
a Correlations between cluster PCR prevalence and seroprevalence overall and stratified by age of monitoring population. **b** Correlations between PCR prevalence and TF prevalence overall and stratified by age of monitoring population. In all panels, medians across clusters for each study population are represented by larger points with black outline. Each plot includes the identity line (dotted) and Pearson correlations at the cluster- and population-levels. 95% confidence intervals (CIs) are based on 1,000 bootstrapped samples, holding populations fixed and resampling clusters with replacement. Population-level values are included for Andabet, Dera, Woreta town, and Alefa, Ethiopia, but cluster-level PCR prevalence was not available for these populations. Abbreviations: ETH = Ethiopia; MWI = Malawi; NER = Niger; TZA = Tanzania.

Abbreviations: ETH = Ethiopia; NER = Niger; TZA = Tanzania; MWI = Malawi

Figure 6. Identification of clusters with *C. trachomatis* infection using seroprevalence.
(**a**) Sensitivity and specificity curves for identification of clusters with any *Ct* infections based on different seroprevalence thresholds among children 1-9 years old (n = 281 clusters, 99 clusters with PCR>0%). Vertical lines delineate sensitivity at 90% (solid line, 13.5% seroprevalence) and 80% (dotted line, 22.5% seroprevalence). Thin lines show sensitivity for each study population with cluster-level PCR measurements. Points at bottom of plot mark seroprevalence estimates for each study population. (**b**) Receiver operating characteristic (ROC) curves for all clusters (thick black line) and for each population (thin colored lines) with overall area-under-the-curve (AUC).